论文部分内容阅读
支气管哮喘是由于多种炎性细胞,特别是嗜酸性粒细胞、肥大细胞和T淋巴细胞等参与的气道慢性炎症。这种慢性炎症与气道高反应性传统的发生和发张有关。同时,支气管哮喘是世界范围的慢性呼吸道疾病,其发病率和患病率不断上升。哮喘的发病是遗传和环境两方面因素共同作用的结果。临床上表现为反复发作的喘息、气急、胸闷、咳嗽等症状,常在夜间和(或)清晨发作、加剧,大多数患者可经药物治疗得到控制。治疗多是通过口服和静脉给药,我科自2013年9月-2014年9月共收治支气管哮喘患者45例,在传统治疗基础上配合吸入β-受体兴奋剂、糖皮质激素、胆碱能受体拮抗剂气雾剂取得非常满意的疗效,现报告如下。
Bronchial asthma is a chronic inflammation of the airways involved in a variety of inflammatory cells, especially eosinophils, mast cells and T lymphocytes. This chronic inflammation is associated with the traditional occurrence and development of airway hyperresponsiveness. In the meantime, bronchial asthma is a worldwide chronic respiratory disease with an increasing prevalence and prevalence. The incidence of asthma is the result of both genetic and environmental factors. Clinically manifested as recurrent wheezing, shortness of breath, chest tightness, cough and other symptoms, often at night and (or) early morning seizures, aggravating the majority of patients can be controlled by medication. Treatment is mostly oral and intravenous administration, our department since September 2013 - September 2014 were treated 45 cases of patients with bronchial asthma, based on the traditional treatment with inhaled β-receptor agonists, glucocorticoid, choline Can accept the antagonist aerosol very satisfied curative effect, report as follows now.